Table 2.

Outcomes of interest from scoping review of smoking status impact on neurological disorders.

Neurological Condition	Disease-specific outcomes
Demyelinating disorders	Conversion of CIS to MS Conversion to progressive forms of MS Relapse occurrence and frequency Progression of Expanded Disability Status Scale Progression of Multiple Sclerosis Severity Score Standardized Paced Auditory Serial Addition Test MS Impact Scale-29 Physical Hospital Anxiety and Depression Scale Development of antibodies to natalizumab and interferon beta-1a Discontinuation of natalizumab, dimethyl fumarate, or fingolimod Changes in contrast-enhancing lesions Changes in neurofilament light chain
Cerebrovascular Disease	Stroke recurrence Post-stroke cardiovascular events Post-stroke mortality Cognitive function tests Fatigue, anxiety, and depression Modified Rankin Score Barthel Index Intracranial aneurysm growth and rupture
Cognitive Disorders	Progression of disease across SCD, MCI, dementia spectrum Reversal of MCI to normal cognition Mini-Mental State Examination score Clinical Dementia Rating Scale Sum of Boxes score Montreal Cognitive Assessment score Risk of death from AD Entorhinal cortex volume Serum biomarkers
Parkinson’s Disease	Unified Parkinson Disease Rating Scale Hoehn and Yahr Scale Schwab and England Score L-Dopa dosage Incident dementia development Montgomery and Aasberg Depression Rating Scale Mini-Mental State Examination score
Amyotrophic Lateral Sclerosis	Survival
Headache	Frequency of cluster headache active periods Length of cluster headache active periods Maximum number of attacks per day Length of cluster headache attacks Intensity of cluster headache attacks

CIS, clinically isolated syndrome; MS, multiple sclerosis; SCD, subjective cognitive decline; MCI, mild cognitive impairment; AD, Alzheimer disease